IDEAYA Biosciences (IDYA)


Market Price (11/19/2026): $26.5 | Market Cap: $2.6 BilSector: Health Care | Industry: Biotechnology

IDEAYA Biosciences (IDYA)


Market Price (11/19/2026): $26.5
Market Cap: $2.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30%

Low stock price volatility
Vol 12M is 46%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Oncology Treatments, Show more.

Weak multi-year price returns
2Y Excs Rtn is -37%, 3Y Excs Rtn is -77%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -463 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1267%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -83%, Rev Chg QQuarterly Revenue Change % is -95%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 166%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -951%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -957%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 409%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20%

Key risks
IDYA key risks include [1] the uncertain clinical and regulatory success of its precision oncology pipeline and [2] its ongoing unprofitability and need for future funding.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30%
1 Low stock price volatility
Vol 12M is 46%
2 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Oncology Treatments, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -37%, 3Y Excs Rtn is -77%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -463 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1267%
5 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -83%, Rev Chg QQuarterly Revenue Change % is -95%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 166%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -951%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -957%
8 Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 409%
9 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20%
10 Key risks
IDYA key risks include [1] the uncertain clinical and regulatory success of its precision oncology pipeline and [2] its ongoing unprofitability and need for future funding.

IDYA in ETFs

Weight = IDYA's share of each fund

VTI0.00%
ITOT0.00%
IWM0.10%
XBI0.51%
IBB0.20%
IWN0.17%
VTWO0.10%
SCHA0.07%
+8 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 17: down 9.7% in one day (S&P 500 down 1.0%)
The stock declined without company-specific news to explain the drop. This occurred on a day when broader market headlines cited slower retail sales dragging on the market.

Down 37.6% since its Aug 25 high (S&P 500 down 4.4%)
The stock declined without specific company news to explain the overall trend, during a period when the broader market also saw weakness. Key declines occurred on November 5, driven by a market reportedly "in a sea of red," and on November 17.

Nov 4: up 3.3% the day after its Nov 3 earnings report (S&P 500 up 1.7%)
The stock rose after its third quarter 2026 earnings report topped revenue and loss estimates, and reported positive clinical data for darovasertib. This occurred as the broader market also moved higher, with headlines indicating a "Blue Wave" and rising pharma stocks.

Show more
Prices as of 11/18/2026

Nov 17: down 9.7% in one day (S&P 500 down 1.0%)
The stock declined without company-specific news to explain the drop. This occurred on a day when broader market headlines cited slower retail sales dragging on the market.

Down 37.6% since its Aug 25 high (S&P 500 down 4.4%)
The stock declined without specific company news to explain the overall trend, during a period when the broader market also saw weakness. Key declines occurred on November 5, driven by a market reportedly "in a sea of red," and on November 17.

Nov 4: up 3.3% the day after its Nov 3 earnings report (S&P 500 up 1.7%)
The stock rose after its third quarter 2026 earnings report topped revenue and loss estimates, and reported positive clinical data for darovasertib. This occurred as the broader market also moved higher, with headlines indicating a "Blue Wave" and rising pharma stocks.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -25.4% change in IDYA stock from 7/31/2026 to 11/18/2026 was primarily driven by a -83.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)731202611182026Change
Stock Price ($)35.5026.49-25.4%
Change Contribution By: 
Total Revenues ($ Mil)22537-83.8%
P/S Multiple14.074.6434.0%
Shares Outstanding (Mil)89103-13.8%
Cumulative Contribution-25.4%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
IDYA-25.4% 
Market (SPY)-2.0%45.4%
Sector (XLV)11.9%47.3%

Fundamental Drivers

The -9.0% change in IDYA stock from 4/30/2026 to 11/18/2026 was primarily driven by a -83.3% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611182026Change
Stock Price ($)29.1026.49-9.0%
Change Contribution By: 
Total Revenues ($ Mil)21937-83.3%
P/S Multiple11.874.6533.3%
Shares Outstanding (Mil)89103-13.9%
Cumulative Contribution-9.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
IDYA-9.0% 
Market (SPY)2.1%32.7%
Sector (XLV)25.1%28.3%

Fundamental Drivers

The -16.9% change in IDYA stock from 10/31/2025 to 11/18/2026 was primarily driven by a -81.5% change in the company's P/S Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)31.8626.49-16.9%
Change Contribution By: 
Total Revenues ($ Mil)737421.9%
P/S Multiple402.774.6-81.5%
Shares Outstanding (Mil)88103-14.1%
Cumulative Contribution-16.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
IDYA-16.9% 
Market (SPY)8.2%30.7%
Sector (XLV)27.7%32.3%

Fundamental Drivers

The -2.5% change in IDYA stock from 10/31/2023 to 11/18/2026 was primarily driven by a -45.4% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202311182026Change
Stock Price ($)27.1726.49-2.5%
Change Contribution By: 
Total Revenues ($ Mil)4537-19.1%
P/S Multiple33.974.6120.5%
Shares Outstanding (Mil)56103-45.4%
Cumulative Contribution-2.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
IDYA-2.5% 
Market (SPY)81.1%37.3%
Sector (XLV)52.9%37.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
IDYA Return69%-23%96%-28%35%-23%89%
Peers Return-22%-48%11%-55%54%34%-58%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
IDYA Win Rate67%58%67%25%58%45% 
Peers Win Rate42%33%45%40%55%42% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
IDYA Max Drawdown-30%-66%-29%-47%-44%-38% 
Peers Max Drawdown-58%-66%-65%-73%-58%-51% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ZNTL, TNGX, KURA, RLAY, BDTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventIDYAS&P 500
2025 US Tariff Shock
  % Loss-29.8%-18.8%
  % Gain to Breakeven42.5%23.1%
  Time to Breakeven24 days79 days
2023 SVB Regional Banking Crisis
  % Loss-25.3%-6.7%
  % Gain to Breakeven33.9%7.1%
  Time to Breakeven12 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-65.5%-24.5%
  % Gain to Breakeven190.1%32.4%
  Time to Breakeven389 days427 days
2020 COVID-19 Crash
  % Loss-55.6%-33.7%
  % Gain to Breakeven125.1%50.9%
  Time to Breakeven52 days140 days

Compare to ZNTL, TNGX, KURA, RLAY, BDTX

In The Past

IDEAYA Biosciences's stock fell -29.8% during the 2025 US Tariff Shock. Such a loss loss requires a 42.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventIDYAS&P 500
2025 US Tariff Shock
  % Loss-29.8%-18.8%
  % Gain to Breakeven42.5%23.1%
  Time to Breakeven24 days79 days
2023 SVB Regional Banking Crisis
  % Loss-25.3%-6.7%
  % Gain to Breakeven33.9%7.1%
  Time to Breakeven12 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-65.5%-24.5%
  % Gain to Breakeven190.1%32.4%
  Time to Breakeven389 days427 days
2020 COVID-19 Crash
  % Loss-55.6%-33.7%
  % Gain to Breakeven125.1%50.9%
  Time to Breakeven52 days140 days

Compare to ZNTL, TNGX, KURA, RLAY, BDTX

In The Past

IDEAYA Biosciences's stock fell -29.8% during the 2025 US Tariff Shock. Such a loss loss requires a 42.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About IDEAYA Biosciences (IDYA)

IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology company dedicated to discovering and developing targeted therapeutics for cancer. The company’s core focus is on "synthetic lethality," an approach that aims to selectively kill cancer cells by exploiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA identifies patient populations using molecular diagnostics, ensuring that their investigational treatments are directed towards those most likely to benefit from a specific therapeutic strategy.

The company's pipeline features lead product candidates in clinical development. IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor, is currently in Phase I trials for patients with solid tumors characterized by methylthioadenosine phosphorylase (MTAP) deletions. Another key asset, IDE196, a protein kinase C (PKC) inhibitor, is undergoing Phase I/II clinical trials for genetically defined cancers that have GNAQ or GNA11 gene mutations, which are notably found in uveal melanoma. Beyond these clinical programs, IDEAYA is also advancing a preclinical pipeline targeting other synthetic lethality pathways, including PARG inhibitors, Pol Theta inhibitors, and WRN inhibitors, each designed for tumors with specific biomarkers such as BRCA mutations or high microsatellite instability.

IDEAYA primarily serves patients suffering from various cancers who possess specific genetic mutations or molecular signatures, allowing for a highly tailored treatment approach. To accelerate its research and development, IDEAYA has established strategic collaborations, including a research agreement with Cancer Research UK and the University of Manchester. Furthermore, the company has forged significant partnerships with pharmaceutical giants like Pfizer Inc. for clinical trials and GlaxoSmithKline plc, underscoring the potential and scientific validation of its innovative cancer therapies.

AI Analysis | Feedback

Here are 1-2 brief analogies for IDEAYA Biosciences (IDYA):

  • Like Moderna or BioNTech, but focused on developing highly targeted cancer therapies instead of vaccines.
  • A smaller, early-stage Amgen or Gilead Sciences, singularly dedicated to discovering groundbreaking precision oncology drugs.

AI Analysis | Feedback

  • IDE397: A methionine adenosyltransferase 2a inhibitor currently in Phase I clinical trial for solid tumors with MTAP deletions.
  • IDE196: A protein kinase C inhibitor in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
  • PARG inhibitor program: A preclinical program developing small molecule inhibitors for tumors with a defined biomarker based on genetic mutations and/or molecular signatures.
  • Pol Theta inhibitor program: A preclinical program developing inhibitors for tumors with BRCA or other homologous recombination deficiency mutations.
  • WRN inhibitor program: A preclinical program developing inhibitors for tumors with high microsatellite instability.

AI Analysis | Feedback

IDEAYA Biosciences (IDYA) is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics. As such, it does not currently sell commercial products directly to individuals or traditional customers in the way a retail or service company would. Instead, IDEAYA Biosciences generates revenue and advances its pipeline through strategic partnerships and collaborations with larger pharmaceutical companies and research institutions. These partners contribute funding, expertise, and resources, making them the primary financial stakeholders and collaborators in IDEAYA's business model. Based on the provided information, IDEAYA Biosciences' major "customers" or strategic partners (who provide funding and support for product development) are:
  • Pfizer Inc. (NYSE: PFE)
  • GlaxoSmithKline plc (NYSE: GSK)

AI Analysis | Feedback

null

AI Analysis | Feedback

Yujiro S. Hata, President, Chief Executive Officer, Founder, and Director

Mr. Hata founded IDEAYA Biosciences in June 2015 as its first employee, CEO, and Director, and led the company's IPO on NASDAQ in May 2019. From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures. Prior to IDEAYA, he was Chief Operating Officer at Flexus Biosciences from 2014 to August 2015, guiding it through its acquisition by Bristol-Myers Squibb in April 2015. He also served as Chief Operating Officer at FLX Bio (later RAPT Therapeutics), a spinout of Flexus Biosciences. From 2010 to 2014, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, including through its acquisition by Amgen. From 2002 to 2010, Mr. Hata held roles including Chief Business Officer at Enanta Pharmaceuticals, where he established a partnership with Abbott Labs that led to the discovery of protease inhibitors in HCV therapies. His background includes earlier roles at McKinsey, ImClone, and Columbia Medical School. His association with 5AM Ventures and leading Flexus Biosciences through an acquisition indicates a pattern of involvement with and successful exits from privately backed and startup companies.

Joshua Bleharski, Ph.D., Chief Financial Officer

Dr. Bleharski was appointed Chief Financial Officer in February 2025. He joined IDEAYA from J.P. Morgan, where he spent nearly 17 years as Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group. In this role, he advised biotechnology companies on financing and strategic transactions valued at over $65 billion. His prior experience includes serving as a Senior Staff Scientist at a private biotechnology company and completing post-doctoral fellowships at LIAI and UCLA School of Medicine. He holds a Ph.D. in Immunology from UCLA and an MBA from UC Berkeley's Haas School of Business.

Michael White, Ph.D., Senior Vice President, Chief Scientific Officer, Head of Research

Dr. White serves as the Chief Scientific Officer and Head of Research for IDEAYA Biosciences.

Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer

Dr. Beaupre is the Chief Medical Officer at IDEAYA Biosciences. He previously served as an Assistant Professor in the Department of Interdisciplinary Oncology at the Moffit Cancer Center. His distinctions include receiving a Clinical Scholars in Oncology Award from the National Cancer Institute. Dr. Beaupre completed his Medical Oncology and Hematology Fellowship and post-doctoral research training at the University of Miami Sylvester Cancer Center.

Theodora (Theo) Ross, M.D., Ph.D., Chief Development Officer

Dr. Ross was appointed Chief Development Officer in February 2026. In this role, she is responsible for leading early clinical development for IDEAYA's oncology pipeline and guiding the company's long-term R&D strategy. Prior to joining IDEAYA, Dr. Ross was Vice President, Head of Early Oncology R&D and Site Head for the Bay Area at AbbVie.

AI Analysis | Feedback

Key Risks to IDEAYA Biosciences (IDYA)

  1. Clinical Trial Failure and Regulatory Approval Risk: IDEAYA Biosciences' primary assets are currently in early-stage clinical trials (Phase I and Phase I/II) or preclinical development. The success of these candidates, such as IDE397 and IDE196, is uncertain. Many drug candidates fail during clinical development due to lack of efficacy, unacceptable safety profiles, or other issues. Even if trials are successful, there is no guarantee that regulatory bodies (like the FDA) will approve the drugs for commercialization. Failure at any stage of development or inability to secure regulatory approval would severely impact the company's prospects and valuation.
  2. Intellectual Property Protection Risk: As a precision medicine oncology company, IDEAYA Biosciences relies heavily on its ability to discover, develop, and protect proprietary compounds and technologies. The company's competitive advantage and future revenue potential depend on obtaining and maintaining patent protection for its product candidates and related intellectual property. If the company is unable to secure strong patent protection, or if its patents are challenged, invalidated, or circumvented by competitors, it could significantly diminish the value of its pipeline and expose it to competition.
  3. Intense Competition in the Oncology Market: The field of oncology drug development is highly competitive, with numerous large pharmaceutical companies and biotechnology firms developing similar or alternative therapies. IDEAYA's product candidates, if approved, would compete with existing treatments and new therapies that are continually being developed by others. The ability to successfully commercialize its products will depend on their efficacy, safety, market acceptance, and competitive pricing, all within a rapidly evolving and competitive landscape.

AI Analysis | Feedback

null

AI Analysis | Feedback

IDEAYA Biosciences (NASDAQ: IDYA) focuses on precision medicine oncology. The addressable markets for its main product candidates are as follows:

  • IDE397 (Methionine Adenosyltransferase 2a Inhibitor): This product targets solid tumors with methylthioadenosine phosphorylase (MTAP) deletions. MTAP deletion is found in approximately 15% of solid tumors globally. The global solid tumor market is projected to reach USD 283.8 billion by 2029. Therefore, the estimated global addressable market for IDE397 is approximately USD 42.6 billion. Additionally, the annual incidence of MTAP-deletion solid tumors across priority types such as non-small cell lung cancer, bladder, gastric, and esophageal cancers is estimated to be greater than 50,000 patients in the U.S., EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • IDE196 (Protein Kinase C Inhibitor): This product is in development for genetically defined cancers having GNAQ or GNA11 gene mutations, primarily metastatic uveal melanoma. GNAQ and GNA11 gene mutations are present in approximately 80% to 90% of uveal melanoma cases. The global uveal melanoma treatment market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2035. This market size is global.

AI Analysis | Feedback

IDEAYA Biosciences (NASDAQ: IDYA) is a precision medicine oncology company with a pipeline focused on synthetic lethality. While analysts have recently adjusted down revenue estimates for 2026, forecasts for 2027 and 2028 indicate a potential increase, driven by the advancement and eventual commercialization of its therapeutic candidates and milestone achievements from strategic collaborations.

Here are 3-5 expected drivers of future revenue growth for IDEAYA Biosciences over the next 2-3 years:

  1. Commercialization of Darovasertib (IDE196) for Uveal Melanoma: Darovasertib, a protein kinase C inhibitor, is IDEAYA's lead product candidate, currently in Phase 2/3 registrational trials for metastatic uveal melanoma (mUM). Topline results for the OptimUM-02 trial, evaluating darovasertib in combination with crizotinib, are anticipated by approximately the last week of March 2026. Furthermore, darovasertib is expected to be in three randomized Phase 3 registrational trials for uveal melanoma (metastatic, neoadjuvant, and adjuvant settings) by the first half of 2026. The company has also received U.S. FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant uveal melanoma. IDEAYA has partnered with Servier for exclusive rights to darovasertib outside the United States, a collaboration that includes an upfront payment, potential milestone payments of up to $320 million, and double-digit royalties on ex-U.S. net sales, while IDEAYA retains all U.S. commercial rights. Commercial readiness activities are ongoing in anticipation of these critical trial results and potential market entry.
  2. Achievement of Development and Commercial Milestone Payments from Strategic Collaborations: IDEAYA has established partnerships with major pharmaceutical companies, which serve as a significant source of current and future revenue through milestone payments. Notable collaborations include the agreement with Servier for darovasertib (outside U.S. rights), and GlaxoSmithKline (GSK) for the Werner Helicase inhibitor program and the Pol Theta program. For the Werner Helicase inhibitor, IDEAYA is eligible for up to $465 million in development and regulatory milestones, $475 million in commercial milestones, and 50% of U.S. net profits, along with tiered royalties on global non-U.S. net sales. A $7 million milestone was earned from GSK upon IND clearance of IDE275 (Werner Helicase) in October 2024. The Pol Theta Helicase program also has a potential $10 million milestone payment from GSK upon Phase 2 expansion. Additional collaborations, such as with Gilead for the IDE397 combination and Biocytogen for the B7H3/PTK7 Topo-Payload BsADC program, offer further potential milestone payments as these programs advance through development.
  3. Advancement and Potential Market Entry of IDE849 (DLL3 TOP1 ADC): IDEAYA is progressing IDE849, a DLL3 TOP1 ADC, with the initiation of a monotherapy registrational study in the second line/refractory setting of small cell lung cancer (SCLC) and/or neuroendocrine carcinomas (NEC) targeted by the end of 2026. Preliminary clinical data updates from the IDEAYA-sponsored global Phase 1 trial of IDE849 are also expected by the end of 2026. The successful progression and potential commercialization of IDE849 represent another distinct avenue for product-based revenue growth within the next 2-3 years.
  4. Progression of Other Clinical and Preclinical Synthetic Lethality Pipeline Programs: Beyond darovasertib and IDE849, IDEAYA has a robust pipeline of synthetic lethality programs that are expected to contribute to future revenue growth through continued milestone payments and eventual product launches. These include IDE397 (MAT2A inhibitor), which has ongoing Phase 1/2 combination trials with updated data expected in 2026; PARG inhibitors (IDE161); Pol Theta inhibitors (IDE705/GSK101); and Werner Helicase inhibitors (IDE275/GSK959). The company is also targeting new IND filings for IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), and IDE574 (KAT6/7) in 2025/2026, indicating a continuous stream of potential future therapeutic candidates.

AI Analysis | Feedback

Share Issuance

  • IDEAYA Biosciences granted non-qualified stock options to purchase an aggregate of 346,200 shares to three newly hired employees on February 26, 2026, with an exercise price of $31.90.
  • On January 29, 2026, the company granted non-qualified stock options to purchase an aggregate of 44,200 shares to a newly hired employee, with an exercise price of $32.99.

Inbound Investments

  • IDEAYA Biosciences reported approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, which is projected to fund operations into 2030.
  • The company received a $210.0 million upfront payment from Servier in 2025 related to an exclusive license agreement for darovasertib.
  • IDEAYA has strategic partnerships, including one with GlaxoSmithKline (GSK) that could yield up to approximately $3 billion in aggregate cash milestones across its MAT2A, Pol Theta, and Werner Helicase programs.

Capital Expenditures

  • Capital expenditures for IDEAYA Biosciences were $2.64 million in 2021, $3.44 million in 2022, and $2.37 million in 2023.
  • In 2024, capital expenditures were $3.86 million, and in 2025, they were $2.37 million.

Better Bets vs. IDEAYA Biosciences (IDYA)

Peer Outperformance in Biotechnology

IDYA has outperformed 82% of its 369 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that IDYA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
58%
of 452 industry peers · -21.4% return
3Y
58%
of 399 industry peers · -12.8% return
5Y
82%
of 369 industry peers · 13.0% return
No Biotechnology peer with a comparable growth profile has beaten IDYA by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is IDYA's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology ← 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

IDYAZNTLTNGXKURARLAYBDTXMedian
NameIDEAYA B.Zentalis.Tango Th.Kura Onc.Relay Th.Black Di. 
Mkt Price26.501.4021.887.3816.511.4211.95
Mkt Cap2.70.13.80.73.60.11.7
Rev LTM3700791005
Op Inc LTM-463-151-229-313-320-46-271
FCF LTM-350-134-150-89-214-33-142
FCF 3Y Avg-203-147-140-58-248-24-143
CFO LTM-347-134-150-86-214-33-142
CFO 3Y Avg-200-147-139-56-248-24-143

Growth & Margins

IDYAZNTLTNGXKURARLAYBDTXMedian
NameIDEAYA B.Zentalis.Tango Th.Kura Onc.Relay Th.Black Di. 
Rev Chg LTM-83.0%-100.0%-100.0%-23.8%23.9%-100.0%-91.5%
Rev Chg 3Y Avg1,737.1%--10.3%--17.9%--10.3%
Rev Chg Q-95.1%--100.0%10.1%---95.1%
QoQ Delta Rev Chg LTM-84.4%--100.0%2.7%0.0%--42.2%
Op Inc Chg LTM-121.7%1.9%-107.1%-30.4%2.1%-485.4%-68.8%
Op Inc Chg 3Y Avg-67.8%13.5%-37.8%-27.2%4.0%-121.3%-32.5%
Op Mgn LTM-1,267.4%---394.3%-3,094.6%--1,267.4%
Op Mgn 3Y Avg-2,365.1%----3,652.1%--3,008.6%
QoQ Delta Op Mgn LTM-1,174.7%--17.6%-95.2%--95.2%
CFO/Rev LTM-950.8%---107.9%-2,067.8%--950.8%
CFO/Rev 3Y Avg-1,604.9%----2,614.6%--2,109.8%
FCF/Rev LTM-957.4%---112.4%-2,067.8%--957.4%
FCF/Rev 3Y Avg-1,638.1%----2,623.4%--2,130.8%

Valuation

IDYAZNTLTNGXKURARLAYBDTXMedian
NameIDEAYA B.Zentalis.Tango Th.Kura Onc.Relay Th.Black Di. 
Mkt Cap2.70.13.80.73.60.11.7
P/S74.7--8.4349.6-74.7
P/Op Inc-5.9-0.8-16.7-2.1-11.3-1.8-4.0
P/EBIT-5.9-0.8-16.7-2.3-11.3-1.8-4.1
P/E-6.5-0.8-18.3-2.3-12.3-1.9-4.4
P/CFO-7.9-0.9-25.4-7.7-16.9-2.4-7.8
Total Yield-15.4%-123.1%-5.5%-44.4%-8.1%-53.6%-29.9%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-6.3%-82.0%-11.3%-2.8%-20.5%-15.3%-13.3%
D/E0.00.30.00.00.00.20.0
Net D/E-0.3-1.7-0.2-0.7-0.2-1.1-0.5

Returns

IDYAZNTLTNGXKURARLAYBDTXMedian
NameIDEAYA B.Zentalis.Tango Th.Kura Onc.Relay Th.Black Di. 
1M Rtn-21.6%-39.1%-7.0%-21.2%-3.4%-21.5%-21.4%
3M Rtn-31.8%-63.4%-13.2%-41.1%-20.4%-35.2%-33.5%
6M Rtn-10.6%-62.3%3.8%-28.6%26.8%-60.6%-19.6%
12M Rtn-21.4%2.9%173.5%-33.4%153.6%-64.2%-9.2%
3Y Rtn-12.7%-87.7%187.9%-22.8%91.5%-33.6%-17.8%
1M Excs Rtn-21.2%-37.5%-9.5%-22.2%-6.7%-27.6%-21.7%
3M Excs Rtn-29.3%-60.5%-4.0%-34.0%-13.3%-31.0%-30.2%
6M Excs Rtn-10.4%-62.0%4.0%-28.4%27.0%-60.3%-19.4%
12M Excs Rtn-31.7%-5.4%163.0%-43.2%138.2%-75.7%-18.5%
3Y Excs Rtn-77.4%-156.5%120.9%-83.7%46.0%-92.9%-80.5%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Research and development for oncology-focused precision medicine2197235128
Total2197235128


Assets by Segment
$ Mil20192018
Research and development for oncology-focused precision medicine11397
Total11397


Price Behavior

Price Behavior
Market Price$26.49 
Market Cap ($ Bil)2.7 
First Trading Date05/23/2019 
Distance from 52W High-37.6% 
   50 Days200 Days
DMA Price$34.81$33.77
DMA Trenddowndown
Distance from DMA-23.9%-21.6%
 3M1YR
Volatility44.4%46.1%
Downside Capture213.14129.90
Upside Capture113.79103.24
Correlation (S&P 500)42.6%30.0%
IDYA Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.860.910.830.790.861.14
Up Beta-5.030.02-0.020.771.351.07
Down Beta-0.540.510.260.20-0.090.74
Up Capture14%39%89%113%96%212%
Bmk +ve Days12182862130427
Stock +ve Days8173062122376
Down Capture265%197%152%92%107%109%
Bmk -ve Days10253664121325
Stock -ve Days14263463128371

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with IDYA
IDYA-20.6%46.1%-0.37-
Sector ETF (XLV)21.5%17.0%0.9632.3%
Equity (SPY)10.9%13.8%0.4931.4%
Gold (GLD)-8.2%29.0%-0.3016.9%
Commodities (DBC)28.8%21.5%1.07-15.9%
Real Estate (VNQ)11.2%14.2%0.5012.1%
Bitcoin (BTCUSD)-29.6%43.7%-0.6925.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with IDYA
IDYA3.9%58.1%0.29-
Sector ETF (XLV)8.0%15.4%0.3330.5%
Equity (SPY)11.0%17.3%0.4632.7%
Gold (GLD)14.5%19.2%0.605.9%
Commodities (DBC)6.8%19.6%0.240.4%
Real Estate (VNQ)1.1%19.0%-0.0525.0%
Bitcoin (BTCUSD)-0.0%51.4%0.1819.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with IDYA
IDYA9.4%72.6%0.47-
Sector ETF (XLV)12.1%16.8%0.5925.6%
Equity (SPY)14.9%18.0%0.7026.9%
Gold (GLD)10.9%16.6%0.536.5%
Commodities (DBC)7.2%18.2%0.316.1%
Real Estate (VNQ)5.8%20.7%0.2422.3%
Bitcoin (BTCUSD)57.1%66.3%0.9713.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity8.2 Mil
Short Interest: % Change Since 10152026-9.3%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest8.9 days
Basic Shares Quantity102.9 Mil
Short % of Basic Shares8.0%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/2026-1.0%1.2% 
8/4/20262.0%3.8%12.9%
5/5/2026-0.3%-2.7%-1.7%
2/17/20261.6%6.1%13.2%
11/4/2025-2.8%-1.5%14.8%
8/5/2025-3.5%-8.6%3.0%
5/6/2025-13.3%-10.4%3.1%
2/13/2025-5.4%-1.0%-15.4%
...
SUMMARY STATS   
# Positive111214
# Negative141310
Median Positive2.6%1.8%12.9%
Median Negative-2.5%-3.3%-10.1%
Max Positive14.6%26.0%52.7%
Max Negative-34.8%-34.8%-20.0%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/2026-1.0%1.2% 
8/4/20262.0%3.8%12.9%
5/5/2026-0.3%-2.7%-1.7%
2/17/20261.6%6.1%13.2%
11/4/2025-2.8%-1.5%14.8%
8/5/2025-3.5%-8.6%3.0%
5/6/2025-13.3%-10.4%3.1%
2/13/2025-5.4%-1.0%-15.4%
11/4/20244.9%9.4%-6.8%
8/6/2024-2.7%1.6%4.1%
5/7/2024-0.8%-4.7%-8.0%
2/20/2024-6.6%-2.0%-6.0%
11/7/20231.1%0.9%5.7%
8/10/20232.8%1.9%12.9%
5/9/202314.6%11.5%30.8%
3/7/20236.2%-5.2%-16.7%
11/8/20222.6%-3.3%0.2%
8/15/2022-34.8%-34.8%-20.0%
5/10/202212.6%26.0%52.7%
3/15/2022-2.3%-4.3%-12.2%
11/15/20211.5%0.8%-6.4%
8/10/2021-1.6%-0.9%16.3%
5/10/20211.3%1.7%13.9%
3/23/2021-1.6%-2.6%-17.2%
11/12/2020-1.5%1.2%9.3%
SUMMARY STATS   
# Positive111214
# Negative141310
Median Positive2.6%1.8%12.9%
Median Negative-2.5%-3.3%-10.1%
Max Positive14.6%26.0%52.7%
Max Negative-34.8%-34.8%-20.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202608/04/202610-Q
03/31/202605/05/202610-Q
12/31/202502/17/202610-K
09/30/202511/04/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/18/202510-K
09/30/202411/04/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202302/20/202410-K
09/30/202311/07/202310-Q
06/30/202308/10/202310-Q
03/31/202305/09/202310-Q
12/31/202203/07/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202608/04/202610-Q
03/31/202605/05/202610-Q
12/31/202502/17/202610-K
09/30/202511/04/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/18/202510-K
09/30/202411/04/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202302/20/202410-K
09/30/202311/07/202310-Q
06/30/202308/10/202310-Q
03/31/202305/09/202310-Q
12/31/202203/07/202310-K
09/30/202211/08/202210-Q
06/30/202208/15/202210-Q
03/31/202205/10/202210-Q
12/31/202103/18/202210-K
09/30/202111/15/202110-Q
06/30/202108/10/202110-Q
03/31/202105/10/202110-Q
12/31/202003/23/202110-K
09/30/202011/12/202010-Q
06/30/202008/12/202010-Q
03/31/202005/12/202010-Q
12/31/201903/24/202010-K

Insider Activity

Updated 10/8/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Hata, Yujiro SPresident and CEODirectSell1008202637.4126,338985,39725,841,317Form
2Ruiz, Briseno AndresChief Accounting OfficerDirectSell709202640.019,550382,1311,059,003Form
3Stein, Jeffrey DirectBuy302202632.9650,0001,647,8901,788,982Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Hata, Yujiro SPresident and CEODirectSell1008202637.4126,338985,39725,841,317Form
2Ruiz, Briseno AndresChief Accounting OfficerDirectSell709202640.019,550382,1311,059,003Form
3Stein, Jeffrey DirectBuy302202632.9650,0001,647,8901,788,982Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
GSK plc$44.4 Mil7.4%13Hold13F
First Turn Management, LLC$29.1 Mil3.3%33ADD +20.8%13F
Redmile Group, LLC$17.4 Mil1.1%35TRIM -29.8%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Turn Management, LLC$29.1 Mil3.3%33ADD +20.8%13F
Active ManagerValue% of PortfolioTotal PositionsQoQAs OfFiling
Iron Triangle Partners LP$16.2 Mil1.8%27ExitedDec 31, 202513F
Redmile Group, LLC$17.4 Mil1.1%35TRIM -29.8%Mar 31, 202613F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
GSK plc$44.4 Mil7.4%13Hold13F
First Turn Management, LLC$29.1 Mil3.3%33ADD +20.8%13F
Redmile Group, LLC$17.4 Mil1.1%35TRIM -29.8%13F
Core Cache Last Updated: 11/18/2026